Bristol-Myers gets positive Hep C opinion from EMA committee

NEW YORK (MarketWatch) -- Bristol Myers-Squibb Co.
BMY, +0.20%
said it has received a positive opinion for a Hepatitis C treatment from a committee of the European Medicines Agency. The opinion recommends the use of Daklinza in combination with other products for the treatment of the virus in adults. "This is the first positive opinion given by the CHMP for an NS5A complex inhibitor and will now be reviewed by the European Commission, which has the authority to approve medicines for the European Union," the company said in a statement. Daklinza has already been granted an accelerated review process by European regulators, and applications are pending in the U.S. and Japan.

Intraday Data provided by SIX Financial Information and subject to terms of use. Historical and current end-of-day data provided by SIX Financial Information. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.